Indexing metadata

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Dublin Core PKP Metadata Items Metadata for this Document
1. Title Title of document Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020
2. Creator Author's name, affiliation, country Natalia Yu. Pshenichnaya; National Medical Research Center of Tuberculosis and Infectious Diseases; Central Research Institute of Epidemiology; Russian Federation
2. Creator Author's name, affiliation, country Elena N. Kareva; Sechenov First Moscow State Medical University (Sechenov University); Pirogov Russian National Research Medical University; Russian Federation
2. Creator Author's name, affiliation, country Irina A. Leneva; Mechnikov Research Institute of Vaccines and Serums; Russian Federation
2. Creator Author's name, affiliation, country Vilya A. Bulgakova; Pirogov Russian National Research Medical University; Central Clinical Hospital; Russian Federation
2. Creator Author's name, affiliation, country Irina E. Kravchenko; Kazan State Medical University; Russian Federation
2. Creator Author's name, affiliation, country Irina V. Nikolaeva; Kazan State Medical University; Russian Federation
2. Creator Author's name, affiliation, country Antonina I. Grekova; Smolensk State Medical University; Russian Federation
2. Creator Author's name, affiliation, country Antonina P. Ivanova; Kursk State Medical University; Russian Federation
2. Creator Author's name, affiliation, country Larisa V. Puzyreva; Omsk State Medical University; Russian Federation
2. Creator Author's name, affiliation, country Guzel M. Khasanova; Bashkir State Medical University; Russian Federation
2. Creator Author's name, affiliation, country Svetlana N. Orlova; Ivanovo State Medical Academy; Russian Federation
2. Creator Author's name, affiliation, country Elena P. Tikhonova; Voino-Yasenetsky Krasnoyarsk State Medical University; Russian Federation
2. Creator Author's name, affiliation, country Vladimir A. Petrov; Tsyb Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology; Obninsk Institute for Nuclear Power Engineering; Russian Federation
2. Creator Author's name, affiliation, country Oleg V. Malinin; Izhevsk State Medical Academy; Russian Federation
2. Creator Author's name, affiliation, country Natalia V. Kolaeva; Sechenov First Moscow State Medical University (Sechenov University); Russian Federation
2. Creator Author's name, affiliation, country Elena V. Volchkova; Sechenov First Moscow State Medical University (Sechenov University); Russian Federation
2. Creator Author's name, affiliation, country Nina N. Kanshina; Sechenov First Moscow State Medical University (Sechenov University); Russian Federation
2. Creator Author's name, affiliation, country Vladimir P. Chulanov; National Medical Research Center of Tuberculosis and Infectious Diseases; Sechenov First Moscow State Medical University (Sechenov University); Russian Federation
3. Subject Discipline(s)
3. Subject Keyword(s) coronaviruses; SARS-CoV-2; COVID-19; antiviral therapy; umifenovir; lopinavir; ritonavir; hydroxychloroquine; interferon
4. Description Abstract

Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness.

Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age – 48.7±18.1 (median – 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median – 54 vs 21 years; p<0.001), higher body mass index (27.8 vs 23.4; p<0.001), prevalence of chronic diseases (75.3% vs 8.5%; p<0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.8±6.1 vs 4.2±2.7 days; p<0.001) and catarrhal symptoms duration (10.2±5.4 vs 6.1±4.1 days; p<0.001).

Results. During hospitalization 92% of the patients received AVT, 77% – antibiotics, and 16% – corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.7±5.5 vs 11.7±5.5 days; p<0.001) and catarrhal symptoms duration (8.8±5.1 vs 12.0±4.9 days; p<0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.9±7.5 vs 11.7±5.5; p<0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics.

Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.

5. Publisher Organizing agency, location LLC Obyedinennaya Redaktsiya
6. Contributor Sponsor(s)
7. Date (DD-MM-YYYY) 15.11.2021
8. Type Status & genre Peer-reviewed Article
8. Type Type Research Article
9. Format File format
10. Identifier Uniform Resource Identifier https://ter-arkhiv.ru/0040-3660/article/view/99553
10. Identifier Digital Object Identifier (DOI) 10.26442/00403660.2021.11.201206
11. Source Title; vol., no. (year) Terapevticheskii arkhiv; Vol 93, No 11 (2021)
12. Language English=en ru
13. Relation Supp. Files Fig. 1. COVID-19 cases in the Russian Federation during the study period (black line) and the number of patients included in the study. (85KB)
14. Coverage Geo-spatial location, chronological period, research sample (gender, age, etc.)
15. Rights Copyright and permissions Copyright (c) 2021 Consilium Medicum
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.